UK Early Access For BioCryst’s Hereditary Angioedema Drug
Berotralstat Could Overcome ‘Serious Limitations’ Of Existing Therapies
The HAE product, which meets the four criteria for pre-licensing use under the UK’s early access scheme, is currently undergoing regulatory evaluation in the EU, the US and Japan, with approval decisions expected in the last two countries next month.
